The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.

Evanthia BletsaStavroula A PaschouVasiliki TsigkouPanagiota K StampouloglouVasiliki VasileiouGeorgia N KassiEvangelos OikonomouGerasimos Siasos

Published in: Hormones (Athens, Greece) (2022)

This systematic review provides evidence that allopurinol may reduce CVD risk in patients with T2D. Randomized, placebo-controlled trials should be performed in order to confirm these findings and identify specific subgroups of patients who will benefit most.

Keyphrases

placebo controlled
double blind
systematic review
phase iii
phase ii
meta analyses
clinical trial
study protocol
phase ii study
open label
randomized controlled trial
rectal cancer